These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30298278)

  • 1. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
    Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD
    Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD
    Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Dowling G; Wallach J; Halberstadt AL
    Drug Test Anal; 2019 Aug; 11(8):1122-1133. PubMed ID: 31083768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Hoang K; Wallach J; Halberstadt AL
    Drug Test Anal; 2016 Sep; 8(9):891-902. PubMed ID: 26456305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Odland AU; Klein AK; Dowling G; Dempster NM; Wallach J; Passie T; Halberstadt AL
    Drug Test Anal; 2020 Jun; 12(6):812-826. PubMed ID: 32180350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives.
    Huang X; Marona-Lewicka D; Pfaff RC; Nichols DE
    Pharmacol Biochem Behav; 1994 Mar; 47(3):667-73. PubMed ID: 8208787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).
    Brandt SD; Kavanagh PV; Twamley B; Westphal F; Elliott SP; Wallach J; Stratford A; Klein LM; McCorvy JD; Nichols DE; Halberstadt AL
    Drug Test Anal; 2018 Feb; 10(2):310-322. PubMed ID: 28585392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
    Nichols DE; Frescas S; Marona-Lewicka D; Kurrasch-Orbaugh DM
    J Med Chem; 2002 Sep; 45(19):4344-9. PubMed ID: 12213075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Dowling G; Halberstadt AL
    Drug Test Anal; 2020 Oct; 12(10):1514-1521. PubMed ID: 32803833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Return of the lysergamides. Part II: Analytical and behavioural characterization of N
    Brandt SD; Kavanagh PV; Westphal F; Elliott SP; Wallach J; Colestock T; Burrow TE; Chapman SJ; Stratford A; Nichols DE; Halberstadt AL
    Drug Test Anal; 2017 Jan; 9(1):38-50. PubMed ID: 27265891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.
    Brandt SD; Kavanagh PV; Westphal F; Pulver B; Schwelm HM; Whitelock K; Stratford A; Auwärter V; Halberstadt AL
    Drug Test Anal; 2022 Aug; 14(8):1503-1518. PubMed ID: 35524430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Pulver B; Morton K; Stratford A; Dowling G; Halberstadt AL
    Drug Test Anal; 2022 Apr; 14(4):733-740. PubMed ID: 34837347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
    Halberstadt AL; Chatha M; Klein AK; Wallach J; Brandt SD
    Neuropharmacology; 2020 May; 167():107933. PubMed ID: 31917152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
    Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
    J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the 5-HT
    Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.
    Klein LM; Cozzi NV; Daley PF; Brandt SD; Halberstadt AL
    Neuropharmacology; 2018 Nov; 142():231-239. PubMed ID: 29499272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines.
    Halberstadt AL; Luethi D; Hoener MC; Trachsel D; Brandt SD; Liechti ME
    Psychopharmacology (Berl); 2023 Jan; 240(1):115-126. PubMed ID: 36477925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N
    Brandt SD; Kavanagh PV; Westphal F; Pulver B; Schwelm HM; Stratford A; Auwärter V; Halberstadt AL
    Drug Test Anal; 2024 Feb; 16(2):187-198. PubMed ID: 37321559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).
    Schindler EA; Dave KD; Smolock EM; Aloyo VJ; Harvey JA
    Pharmacol Biochem Behav; 2012 Mar; 101(1):69-76. PubMed ID: 22197710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.